Nutshell Therapeutics utilizes its AlloStar allosteric drug discovery platform, which combines proprietary AI algorithms with biochemistry and biophysics, to identify small molecules that target undruggable proteins. This technology enables the development of subtype-selective inhibitors and protein modulators, addressing the challenge of creating effective treatments for solid tumors and other diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Many proteins implicated in diseases like cancer have been considered "undruggable" due to a lack of accessible binding sites for traditional small-molecule drugs. Developing effective treatments for these targets requires innovative approaches that can modulate protein function through alternative mechanisms.
Solution
Nutshell Therapeutics is developing a new class of small-molecule drugs that target traditionally undruggable proteins by leveraging allosteric modulation. Their AlloStar platform combines proprietary AI algorithms with biochemistry and biophysics to identify compounds that bind to novel allosteric sites, thereby altering protein conformation and function. This approach enables the creation of subtype-selective inhibitors, protein activators, and modulators of protein-protein interactions, opening up new possibilities for treating solid tumors and other diseases. The platform can also identify molecules that stabilize intrinsically disordered proteins.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapies for cancer and other diseases with previously undruggable targets.
Features
- AlloStar: AI-driven allosteric drug discovery platform
- Identification of subtype-selective allosteric inhibitors
- Discovery of mutant-selective allosteric inhibitors
- Development of enzyme allosteric activators
- Design of protein-protein interaction modulators
- Identification of disordered protein stabilizer modulators
- Pipeline includes programs targeting p53 Y220C and BIC for solid tumors, and FIC for metabolism